Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Soft Tissue Sarcoma Market Research Report Information By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, and Radiation Therapy), By Disease Type (Local Sarcoma, Regional Sarcoma, and Metastatic Sarcoma), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032


ID: MRFR/Pharma/3862-HCR | 90 Pages | Author: Rahul Gotadki| May 2024

Soft Tissue Sarcoma Market Segmentation


Global Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




  • Targeted Therapy




  • Chemotherapy




  • Anti-Angiogenesis Drugs




  • Radiation Therapy




Global Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




  • Local Sarcoma




  • Regional Sarcoma




  • Metastatic Sarcoma




Global Soft Tissue Sarcoma Regional Outlook (USD Billion, 2019-2030)




  • North America Outlook (USD Billion, 2019-2030)




  • North America Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




    • Targeted Therapy




    • Chemotherapy




    • Anti-Angiogenesis Drugs




    • Radiation Therapy






  • North America Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




    • Local Sarcoma




    • Regional Sarcoma




    • Metastatic Sarcoma




    • US Outlook (USD Billion, 2019-2030)




    • US Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




      • Targeted Therapy




      • Chemotherapy




      • Anti-Angiogenesis Drugs




      • Radiation Therapy






    • US Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




      • Local Sarcoma




      • Regional Sarcoma




      • Metastatic Sarcoma






    • Canada Outlook (USD Billion, 2019-2030)




    • Canada Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




      • Targeted Therapy




      • Chemotherapy




      • Anti-Angiogenesis Drugs




      • Radiation Therapy














    • Canada Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




      • Local Sarcoma




      • Regional Sarcoma




      • Metastatic Sarcoma







  • Europe Outlook (USD Billion, 2019-2030)




  • Europe Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




    • Targeted Therapy




    • Chemotherapy




    • Anti-Angiogenesis Drugs




    • Radiation Therapy






  • Europe Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




    • Local Sarcoma




    • Regional Sarcoma




    • Metastatic Sarcoma




    • Germany Outlook (USD Billion, 2019-2030)




    • Germany Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




      • Targeted Therapy




      • Chemotherapy




      • Anti-Angiogenesis Drugs




      • Radiation Therapy






    • Germany Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




      • Local Sarcoma




      • Regional Sarcoma




      • Metastatic Sarcoma






    • France Outlook (USD Billion, 2019-2030)




    • France Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




      • Targeted Therapy




      • Chemotherapy




      • Anti-Angiogenesis Drugs




      • Radiation Therapy






    • France Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




      • Local Sarcoma




      • Regional Sarcoma




      • Metastatic Sarcoma






    • UK Outlook (USD Billion, 2019-2030)




    • UK Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




      • Targeted Therapy




      • Chemotherapy




      • Anti-Angiogenesis Drugs




      • Radiation Therapy






    • UK Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




      • Local Sarcoma




      • Regional Sarcoma




      • Metastatic Sarcoma






    • Italy Outlook (USD Billion, 2019-2030)




    • Italy Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




      • Targeted Therapy




      • Chemotherapy




      • Anti-Angiogenesis Drugs




      • Radiation Therapy






    • Italy Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




      • Local Sarcoma




      • Regional Sarcoma




      • Metastatic Sarcoma






    • Rest of Europe Outlook (USD Billion, 2019-2030)




    • Rest of Europe Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




      • Targeted Therapy




      • Chemotherapy




      • Anti-Angiogenesis Drugs




      • Radiation Therapy






    • Rest of Europe Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




      • Local Sarcoma




      • Regional Sarcoma




      • Metastatic Sarcoma








  • Asia-Pacific Outlook (USD Billion, 2019-2030)




  • Asia-Pacific Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




    • Targeted Therapy




    • Chemotherapy




    • Anti-Angiogenesis Drugs




    • Radiation Therapy






  • Asia-Pacific Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




    • Local Sarcoma




    • Regional Sarcoma




    • Metastatic Sarcoma




    • China Outlook (USD Billion, 2019-2030)




    • China Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




      • Targeted Therapy




      • Chemotherapy




      • Anti-Angiogenesis Drugs




      • Radiation Therapy






    • China Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




      • Local Sarcoma




      • Regional Sarcoma




      • Metastatic Sarcoma






    • India Outlook (USD Billion, 2019-2030)




    • India Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




      • Targeted Therapy




      • Chemotherapy




      • Anti-Angiogenesis Drugs




      • Radiation Therapy














    • India Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




      • Local Sarcoma




      • Regional Sarcoma




      • Metastatic Sarcoma






    • Japan Outlook (USD Billion, 2019-2030)




    • Japan Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




      • Targeted Therapy




      • Chemotherapy




      • Anti-Angiogenesis Drugs




      • Radiation Therapy






    • Japan Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




      • Local Sarcoma




      • Regional Sarcoma




      • Metastatic Sarcoma






    • South Korea Outlook (USD Billion, 2019-2030)




    • South Korea Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




      • Targeted Therapy




      • Chemotherapy




      • Anti-Angiogenesis Drugs




      • Radiation Therapy






    • South Korea Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




      • Local Sarcoma




      • Regional Sarcoma




      • Metastatic Sarcoma






    • Australia Outlook (USD Billion, 2019-2030)




    • Australia Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




      • Targeted Therapy




      • Chemotherapy




      • Anti-Angiogenesis Drugs




      • Radiation Therapy













    • Australia Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




      • Local Sarcoma




      • Regional Sarcoma




      • Metastatic Sarcoma






    • Rest of Asia-Pacific Outlook (USD Billion, 2019-2030)




    • Rest of Asia-Pacific Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




      • Targeted Therapy




      • Chemotherapy




      • Anti-Angiogenesis Drugs




      • Radiation Therapy






    • Rest of Asia-Pacific Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




      • Local Sarcoma




      • Regional Sarcoma




      • Metastatic Sarcoma







  • Rest of the World Outlook (USD Billion, 2019-2030)




  • Rest of the World Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




    • Targeted Therapy




    • Chemotherapy




    • Anti-Angiogenesis Drugs




    • Radiation Therapy






  • Rest of the World Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




    • Local Sarcoma




    • Regional Sarcoma




    • Metastatic Sarcoma




    • Middle East & Africa Outlook (USD Billion, 2019-2030)




    • Middle East & Africa Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




      • Targeted Therapy




      • Chemotherapy




      • Anti-Angiogenesis Drugs




      • Radiation Therapy






    • Middle East & Africa Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




      • Local Sarcoma




      • Regional Sarcoma




      • Metastatic Sarcoma






    • Latin America Outlook (USD Billion, 2019-2030)




    • Latin America Soft Tissue Sarcoma, By Treatment Outlook (USD Billion, 2019-2030)




      • Targeted Therapy




      • Chemotherapy




      • Anti-Angiogenesis Drugs




      • Radiation Therapy






    • Latin America Soft Tissue Sarcoma, By Disease Type (USD Billion, 2019-2030)




      • Local Sarcoma




      • Regional Sarcoma




      • Metastatic Sarcoma







Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Treatment Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Soft Tissue Sarcoma Market, by Treatment

6.1 Introduction

6.2 Targeted therapy

6.2.1 Market Estimates & Forecast, 2023 - 2030

6.3 Chemotherapy

6.3.1 Market Estimates & Forecast, 2023 - 2030

6.4 Anti-angiogenesis Drug

6.4.1 Market Estimates & Forecast, 2023 - 2030

6.5 Radiation therapy

6.5.1 Market Estimates & Forecast, 2023 - 2030

6.5.2 Internal radiation therapy

6.5.2.1 Market Estimates & Forecast, 2023 - 2030

6.5.3 External radiation therapy

6.5.3.1 Market Estimates & Forecast, 2023 - 2030

Chapter 7. Global Soft Tissue Sarcoma Market, by Disease type

7.1 Introduction

7.2 Local sarcoma

7.2.1 Market Estimates & Forecast, 2023 - 2030

7.3 Regional sarcoma

7.3.1 Market Estimates & Forecast, 2023 - 2030

7.4 Metastatic sarcoma

7.4.1 Market Estimates & Forecast, 2023 - 2030

Chapter 8. Global Soft tissue sarcoma Market, by Distribution channel

8.1 Introduction

8.2 Hospital pharmacies

8.2.1 Market Estimates & Forecast, 2023 - 2030

8.3 Retail pharmacy

8.3.1 Market Estimates & Forecast, 2023 - 2030

8.4 Others

Chapter 9. Global Soft Tissue Sarcoma Market, by End User

9.1 Introduction

9.2 Hospitals

9.2.1 Market Estimates & Forecast, 2023 - 2030

9.3 Oncology centers

9.3.1 Market Estimates & Forecast, 2023 - 2030

9.4 Long Term Care Center

9.4.1 Market Estimates & Forecast, 2023 - 2030

Chapter. 10 Global Soft Tissue Sarcoma Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Rest of the Middle East & Africa

Chapter 11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

Chapter 12 Company Profiles

12.1 GlaxoSmithKline plc

12.1.1 Company Overview

12.1.2 Treatment Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 F. Hoffmann-La Roche Ltd

12.2.1 Company Overview

12.2.2 Treatment Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Pfizer Inc.

12.3.1 Company Overview

12.3.2 Treatment Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Eli Lilly and Company

12.4.1 Company Overview

12.4.2 Treatment/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Johnson & Johnson Services, Inc.

12.5.1 Company Overview

12.5.2 Treatment Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 Teva Pharmaceutical Industries Ltd

12.6.1 Company Overview

12.6.2 Treatment Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Bristol-Myers Squibb Company

12.7.1 Overview

12.7.2 Treatment Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Celgene Corporation

12.8.1 Company Overview

12.8.2 Treatment/Business Segment Overview

12.8.3 Financial Overview

12.8.4 Key Development

12.8.5 SWOT Analysis

12.9 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Pharmaceutical industry

Chapter 14 Appendix

LIST OF TABLES

Table 1 Soft tissue sarcoma Industry Synopsis, 2023 - 2030

Table 2 Soft tissue sarcoma Market Estimates and Forecast, 2023 - 2030, (USD Million)

Table 3 Soft tissue sarcoma Market by Region, 2023 - 2030, (USD Million)

Table 4 Soft tissue sarcoma Market by Treatment, 2023 - 2030, (USD Million)

Table 5 Soft tissue sarcoma Market by Disease types, 2023 - 2030, (USD Million)

Table 6 Soft tissue sarcoma Market by Distribution Channel, 2023 - 2030, (USD Million)

Table 7 Soft tissue sarcoma Market by End Users, 2023 - 2030, (USD Million)

Table 8 North America Soft tissue sarcoma Market by Treatment, 2023 - 2030, (USD Million)

Table 9 North America Soft tissue sarcoma Market by Disease types, 2023 - 2030, (USD Million)

Table 10 North America Soft tissue sarcoma Market by Distribution Channel, 2023 - 2030, (USD Million)

Table 11 North America Soft tissue sarcoma Market by End User, 2023 - 2030, (USD Million)

Table 12 US Soft tissue sarcoma Market by Treatment, 2023 - 2030, (USD Million)

Table 13 US Soft tissue sarcoma Market by Disease types, 2023 - 2030, (USD Million)

Table 14 US Soft tissue sarcoma Market by Distribution Channel, 2023 - 2030, (USD Million)

Table 15 US Soft tissue sarcoma Market by End User, 2023 - 2030, (USD Million)

Table 16 Canada Soft tissue sarcoma Market by Treatment, 2023 - 2030, (USD Million)

Table 17 Canada Soft tissue sarcoma Market by Disease types, 2023 - 2030, (USD Million)

Table 18 Canada Soft tissue sarcoma Market by Distribution Channel, 2023 - 2030, (USD Million)

Table 19 Canada Soft tissue sarcoma Market by End User, 2023 - 2030, (USD Million)

Table 20 South America Soft tissue sarcoma Market by Treatment, 2023 - 2030, (USD Million)

Table 21 South America Soft tissue sarcoma Market by Disease types, 2023 - 2030, (USD Million)

Table 22 South America Soft tissue sarcoma Market by Distribution Channel, 2023 - 2030, (USD Million)

Table 23 South America Soft tissue sarcoma Market by End User, 2023 - 2030, (USD Million)

Table 24 Europe Soft tissue sarcoma Market by Treatment, 2023 - 2030, (USD Million)

Table 25 Europe Soft tissue sarcoma Market by Disease types, 2023 - 2030, (USD Million)

Table 26 Europe Soft tissue sarcoma Market by Distribution Channel, 2023 - 2030, (USD Million)

Table 27 Europe Soft tissue sarcoma Market by End User, 2023 - 2030, (USD Million)

Table 28 Western Europe Soft tissue sarcoma Market by Treatment, 2023 - 2030, (USD Million)

Table 29 Western Europe Soft tissue sarcoma Market by Disease types, 2023 - 2030, (USD Million)

Table 30 Western Europe Soft tissue sarcoma Market by Distribution Channel, 2023 - 2030, (USD Million)

Table 31 Western Europe Soft tissue sarcoma Market by End User, 2023 - 2030, (USD Million)

Table 32 Eastern Europe Soft tissue sarcoma Market by Treatment, 2023 - 2030, (USD Million)

Table 33 Eastern Europe Soft tissue sarcoma Market by Disease types, 2023 - 2030, (USD Million)

Table 34 Eastern Europe Soft tissue sarcoma Market by Distribution Channel, 2023 - 2030, (USD Million)

Table 35 Eastern Europe Soft tissue sarcoma Market by End User, 2023 - 2030, (USD Million)

Table 36 Asia Pacific Soft tissue sarcoma Market by Treatment, 2023 - 2030, (USD Million)

Table 37 Asia Pacific Soft tissue sarcoma Market by Disease types, 2023 - 2030, (USD Million)

Table 38 Asia Pacific Soft tissue sarcoma Market by Distribution Channel, 2023 - 2030, (USD Million)

Table 39 Asia Pacific Soft tissue sarcoma Market by End User, 2023 - 2030, (USD Million)

Table 40 The Middle East & Africa Soft tissue sarcoma Market by Treatment, 2023 - 2030, (USD Million)

Table 41 The Middle East & Africa Soft tissue sarcoma Market by Disease types, 2023 - 2030, (USD Million)

Table 42 The Middle East & Africa Soft tissue sarcoma Market by Distribution Channel, 2023 - 2030, (USD Million)

Table 43 The Middle East & Africa Soft tissue sarcoma Market by End User, 2023 - 2030, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Soft tissue sarcoma Market

Figure 3 Segmentation Market Dynamics for Soft tissue sarcoma Market

Figure 4 Global Soft tissue sarcoma Market Share, by Treatment 2020

Figure 5 Global Soft tissue sarcoma Market Share, by Disease types 2020

Figure 6 Global Soft tissue sarcoma Market Share, by Distribution Channel, 2020

Figure 7 Global Soft tissue sarcoma Market Share, by End Users, 2020

Figure 9 Global Soft tissue sarcoma Market Share, by Region, 2020

Figure 10 North America Soft tissue sarcoma Market Share, by Country, 2020

Figure 11 Europe Soft tissue sarcoma Market Share, by Country, 2020

Figure 12 Asia Pacific Soft tissue sarcoma Market Share, by Country, 2020

Figure 13 The Middle East & Africa Soft tissue sarcoma Market Share, by Country, 2020

Figure 14 Global Soft tissue sarcoma Market: Company Share Analysis, 2020 (%)

Figure 15 GlaxoSmithKline plc: Key Financials

Figure 16 GlaxoSmithKline plc: Segmental Revenue

Figure 17 GlaxoSmithKline plc: Geographical Revenue

Figure 18 F. Hoffmann-La Roche Ltd: Key Financials

Figure 19 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 20 F. Hoffmann-La Roche Ltd: Geographical Revenue

Figure 21 Pfizer Inc.: Key Financials

Figure 22 Pfizer Inc.: Segmental Revenue

Figure 23 Pfizer Inc.: Geographical Revenue

Figure 24 Eli Lilly and Company: Key Financials

Figure 25 Eli Lilly and Company: Segmental Revenue

Figure 26 Eli Lilly and Company: Geographical Revenue

Figure 27 Johnson & Johnson Services, Inc..: Key Financials

Figure 28 Johnson & Johnson Services, Inc..: Segmental Revenue

Figure 29 Johnson & Johnson Services, Inc..: Geographical Revenue

Figure 30 Teva Pharmaceutical Industries Ltd: Key Financials

Figure 31 Teva Pharmaceutical Industries Ltd: Segmental Revenue

Figure 32 Teva Pharmaceutical Industries Ltd: Geographical Revenue

Figure 33 Bristol-Myers Squibb Company: Key Financials

Figure 34 Bristol-Myers Squibb Company: Segmental Revenue

Figure 35 Bristol-Myers Squibb Company: Geographical Revenue

Figure 36 Celgene Corporation: Key Financials

Figure 37 Celgene Corporation: Segmental Revenue

Figure 39 Celgene Corporation: Geographical Revenue

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.